Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kezimuke Keli
- Development stage
- Phase 3
- Lead developer
- Xinjiang Altay Region Kazakh Medical Hospital
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Kezimuke Keli is a traditional Kazakh medicine (TKM) developed by the Xinjiang Altay Region Kazakh Medical Hospital. Formulated as oral granules, it is specifically indicated for the treatment of acute uncomplicated lower urinary tract infections. In the framework of Kazakh medical theory, the preparation is used to clear heat, eliminate toxins, and promote diuresis to alleviate symptoms such as urgency, frequency, and painful urination (dysuria). The drug has undergone clinical evaluation in China, including Phase III trials, to establish its efficacy and safety profile as a botanical-based therapy for urological conditions.
- Brand names
- Kezimuke Keli
- Other names
- Kezimuke Granules克孜木克颗粒
Beyond the preview
Go deeper on Kezimuke Keli.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kezimuke Keli.